initi buy pt vike
potenti becom promis treatment non-
alcohol steatohepat nash address multipl metabol issu
associ diseas phase ib demonstr signific
reduct multipl lipid paramet potenti cardiovascular benefit
make valu therapeut candid address lead caus
death diseas differenti competitor
untap blockbust nash space view
trade signific discount compar compani
target nash vike valuat compel compar
enterpris valu madrig share trade discount
believ vike drug strikingli similar characterist
madrig compound
plan data phase ii readout hypercholesterolemia
nafld de-risk opinion convict base strong
compar phase ib data compound impress phase ii data
madrig believ act read-through efficaci
futur nash studi
share strong run see much upsid ahead
believ posit data clariti fda path forward
nash could see share reach target believ futur posit poc data
nash could result madrigal-lik perform
addit vike also complet phase ii trial
hip fractur recoveri larg discount street
project vike book revenu nash
revenu hip fractur recoveri out-year
multipl value-cr catalyst phase ii top-lin result
hypercholesterolemia nafld potenti phase ii/
trial initi nash phase ib proof-of-concept data
gsd ia ind file x-ald updat
partnership discuss potenti indic expans
pt deriv employ sotp dcf discount earn
model compar compani analysi also use gut check risk
rate pt includ clinic regulatori competit commerci
tr target
share forma june follow-on
equival forma june
revenu
tabl content
tabl exhibit
invest thesi buy front phase ii clinic data read
under-valued thr- agonist approach nash
metabol endocrin pipelin ignor
competit yet untap nash space
introduct nash
differenti thr- pathway pleiotrop benefit nash
pleiotrop benefit ideal nafld nash treatment
battl thr- agonist vs
futur clinic pathway nash
diseas background hip fractur
androgen receptor select androgen receptor modul sarm
clinic develop histori
potenti stress urinari incontin pend data gtx ebonosarm
page
tabl exhibit
exhibit revenu build-up model nash
exhibit revenu build-up model hip fractur recoveri
exhibit vike pipelin upcom catalyst
exhibit deriv vike price
exhibit non-alcohol fatti liver diseas relat definit
exhibit multi-hit hypothesi nash
exhibit estim preval nafld nash world-wide
exhibit diseas progress nafl
exhibit patient nafld confirm nash na
exhibit diagnost treatment algorithm nash
exhibit compani engag nash drug develop employ mri-pdff
exhibit surrog endpoint early-stag diseas
exhibit popul studi clinic trial nash
exhibit select thyromimet vitro function assay compar
exhibit select thr- compar
exhibit demonstr potent cholesterol reduct rabbit monkey
exhibit significantli reduc steatosi diet-induc nash mous model
exhibit improv fibrosi diet-induc nash mous model
exhibit clinic develop histori
exhibit lower triglycerid mild hypercholesterolemia patient
exhibit reduc lp apo-b patient mild hypercholesterolemia
exhibit trial design phase ii studi hypercholesterolemia nafld
exhibit select thr- thr- vs
exhibit plasma concentr day follow multipl dose
exhibit cmax day multipl dose studi
exhibit comparison result phase ib studi
exhibit summari nash agent clinic develop
exhibit select deal nash
exhibit annual incid hip fractur
page
exhibit x-ray typic hip fractur
exhibit increas skelet muscl mass femal rat
exhibit benefici effect cortic bone osteoporosi rat model
exhibit promot weight gain non-human primat
exhibit clinic develop histori
exhibit increas lbm muscl strength men
exhibit design phase ii trial
exhibit well-toler
exhibit lbm improv older adult compound treatment
exhibit potenc compar favor enobosarm
exhibit gsd ia pathophysiolog potenti modul lipid
exhibit significantli reduc liver fat gsd ia mous model
exhibit mutat gene lead x-link adrenoleukodystrophi
exhibit led reduct plasma vlcfa-lpc mous model
exhibit reduc vlcfa level tissu
exhibit regulatori mileston sale mileston sale royalti ligand
page
page
strh bull bear price target upsid probabl occur price target upsid probabl occur price target downsid probabl occur achiev peak market penetr nash peak penetr hip fractur recoveri eu gener revenu nash gener revenu hip fractur recoveri out-year model discount earn model ep discount rate dcf clinic net present valu model probabl success nash hip fractur recoveri averag probabl success achiev peak market penetr nash peak penetr hip fractur recoveri eu gener revenu nash gener revenu hip fractur recoveri out-year model discount earn model ep discount rate dcf clinic net present valu model probabl success nash hip fractur recoveri averag probabl success achiev peak market penetr nash peak penetr hip fractur recoveri eu gener revenu nash gener revenu hip fractur recoveri out-year model discount earn model ep discount rate dcf clinic net present valu model probabl success nash hip fractur recoveri averag probabl success appli price estim case vike inc
suntrust robinson humphrey research factset compani report
suntrust robinson humphrey research factset
invest thesi buy front phase ii clinic data read
non-alcohol steatohepat nash common often asymptomat diseas afflict
liver characterist manifest nash includ fat accumul liver inflamm result
liver damag accord nation institut diabet digest kidney diseas
nash affect approxim peopl popul
develop non-alcohol fatti liver nafl eu rest world preval non-
alcohol fatti liver diseas nafld compar current cure fda-approv
therapeut treatment nash treatment aim modifi risk factor control
metabol condit commonli found nash patient obes diabet
due signific size nash patient popul chronic natur diseas
believ nash repres signific commerci opportun model project vike
book revenu treatment nash out-year model
peak market penetr project commerci launch
wholesal acquisit cost wac approxim per patient per year arriv
price use averag price current brand diabet drug approxim
page
senior managementbrian lian ph michael morneaumariann mancinihiroko masamun ph drug fractur debt mm market valu equiti mm mm technolog valu mm nasdaq vktxvike clinical-stag biopharmaceut compani focus develop novel therapi metabol endocrin disord compani clinic program includ phase ii studi nafld hypercholesterolemia phase ii trial hip fractur receveri phase ib studi gsd ia x-ald ind expect trial focus nash also expect diego capresid chief execut officervp financ administrationsvp clinic operationssvp pharmaceut developmentmadrig data vike inc
per patient per year assum price increas per annum follow
assumpt also appli regard clinic develop timelin
initi phase ii/iii studi nash
announc phase ii top-lin studi result nafld hypercholesterolemia
fda phase ii/iii studi design nash
announc top-lin result phase ii/iii studi nash
complet nda submiss standard review
 launch
base case scenario believ could substanti upsid vike
demand favor price depend final safeti efficaci result addit
includ market larger nafld patient popul repres addit upsid
potenti long-term growth investor
exhibit revenu build-up model nash
nash space seen increas number player enter clinic develop past
three five year investig nash agent larg employ divers mechan action
target differ subset nash patient popul highlight divers diseas
view specif thr- agon repres promis approach treatment nash thr-
page
non-alcohol steatohepat nash adult popul rate nafld rate nash rate nash patient rate nash patient market penetr patient treatment per patient per year payment book vike per patient per year sale revenu nash us sale revenu nash book vike steatohepat nash adult popul europ rate nash eu rate nash patient eu rate nash patient eu market penetr patient treatment per patient per year payment book vike per patient per year sale revenu nash eu royalti revenu book vike ww revenu book vike nash vike therapeut inc
agonist demonstr abil lower liver fat stimul mitochondri biogenesi
nash liver reduc lipotox improv overal liver function addit though thr-
agon valid directli effect fibrosi reduct liver fat
shown benefit histolog assess liver biopsi importantli unlik pathway
rais ldl-c triglycerid thr- agonist reduc plasma triglycerid ldl-c
potenti provid cardiovascular benefit nash patient
believ select thr- agonist suitabl candid treatment nash
drug potenti unlock pleiotrop benefit thr- activ avoid
advers effect thr- stimul mechan could potenti address underli
metabol syndrom hallmark featur nash includ steatosi lipotox inflamm
balloon demonstr complet phase ib studi lower plasma
triglycerid ldl-c well atherogen lipid includ lp apo-b potenti
cardiovascular benefit make strong clinic competitor nash arena address
lead caus death within nash popul differenti competitor
nash space undeni nash gain lot attent pharmaceut
biotechnolog compani due vast unmet medic need sizeabl revenu potenti
first-mov advantag undoubtedli substanti think room one
player space especi given kol believ nash requir
under-valued thr- agonist approach nash
conduct comparable-compani analysi compris biotech compani
compound target nash base analysi current trade discount
median enterpris valu compar univers discount mean
compani compar univers
interestingli compar madrig lead compound also thr- agonist
trade discount approxim share price although madrig
produc promis data lead signific appreci share believ
discrep two compani signific ignor believ could
repres attract entri point substanti opportun particip nash space
under-valued thr- agonist clinic asset
suntrust robinson humphrey research factset
page
metabol endocrin pipelin ignor
addit nash vike multipl candid address metabol
endocrin indic includ hip fractur recoveri glycogen storag
diseas type ia gsd ia x-link adrenoleukodystrophi x-ald
advanc candid pipelin hip fractur recoveri model project
vike book revenu recoveri hip fractur out-year
model peak market penetr project commerci launch
wac approxim per patient per year arriv price
take consider price forteo recombin human parathyroid hormon analog
tymlo human parathyroid hormone-rel peptid analog approxim
per year respect also assum price increas per annum
follow assumpt appli regard clinic develop timelin
final partnership discuss meet fda discuss phase design
hip fractur recoveri
initi phase studi hip fractur recoveri
top-lin result phase studi
complet nda submiss standard review
 launch
exhibit revenu build-up model hip fractur recoveri
base case scenario see substanti upsid vike choos investig
potenti therapeut role stress urinari incontin address larger
page
hip fractur popul incid rate hip incid hip fractur hip fractur patient hip fractur patient yo hip fractur patient elig fractur patient elig market penetr patient treatment per patient payment book vike per patient sale revenu hip fractur royalti revenu book vike fractur popul europ incid rate hip incid hip fractur eu hip fractur patient hip fractur patient yo hip fractur patient elig fractur patient elig eu market penetr patient treatment per patient payment book vike per patient eu sale revenu hip fractur eu royalti revenu book vike ww revenu book vike hip fractur vike therapeut inc
patient popul unmet medic need one three women suffer age
approxim half women year age develop moreov includ
gsd ia x-ald project still earli
develop believ program could repres addit upsid proof-of-
concept data posit
multipl near-term catalyst believ could creat signific valu investor
importantli vike plan report data phase ii studi hypercholesterolemia
nafld encourag prospect data base previou posit
phase ib data recent promis result madrig lead program share
mechan action manag indic strong interest pursu
nash plan initi nash trial base posit outcom on-going
vike also on-going discuss regard partnership hip fractur recoveri
plan report result phase ii studi moreov note posit
data gtx phase ii studi enobosarm expect report octob could
creat signific valu appear higher peak efficaci levitor ani
la muscl significantli lower dose head-to-head preclin studi compar
enobosarm potenc addit vike expect announc data phase ib studi
gsd ia file ind x-ald
exhibit vike pipelin upcom catalyst
suntrust robinson humphrey research vike corpor present
page
catalystspotenti initialt phase ii/iii studi nashresult phase ii studi hypercholesterolemia nafld result phase ii studi patient recov hip fractureresult phase ib studi gsd iaind submiss x-aldglp anim toxic data includ potenti ind nash vike inc
valu vike share via three distinct methodolog discount earn model
discount estim earn per share first year meaning revenu back month
current time period appli reason market centric multipl discount rate
take account competit landscap probabl success assum
profit vike fulli dilut estim ep appli multipl
in-lin industri averag profit biotech compani base forward
ep discount back take consider clinic technolog
regulatori commerci risk associ develop commerci success potenti
vike asset applic metric result target price
also use risk-adjust discount cash flow dcf model discount project futur cash
flow vike reach target price revenu build-up model estim cash
flow compani assum averag probabl success
pipelin also employ industry-standard discount rate perpetu growth
rate conserv
third methodolog employ clinic net present valu npv base peak revenu
nash hip fractur recoveri estim peak revenu book
vike approxim nash indic hip fractur recoveri
page
dilut price-to-earnings ratiofi ratefin year growth valu termin valu net dilut share per fulli dilut probabl adjust valu per fulli dilut vike inc
assign success probabl nash hip fractur recoveri base
demonstr clinic profil demonstr date
assign econom nash assum sale royalti
ligand econom nash eu hip
fractur recoveri eu take account number current share outstand
obtain clinic npv
take averag price target discount earn dcf clinic npv model
arriv price target
exhibit deriv vike price target
importantli chosen incorpor gsd ia x-ald
model time earli develop therefor believ program
repres addit upsid model posit proof-of-concept data report
clinic risk efficaci safeti profil encourag phase ib studi
nafld hypercholesterolemia impress met primari endpoint phase
ii trial hip fractur recoveri guarante futur clinic success
regulatori risk despit promis data clinic trial date promis data
report futur pivot trial guarante fda approv
competit risk sever compani develop therapeut treatment nash
believ differenti due pleiotrop benefit nash benign safeti profil
howev compet therapeut may first-to-market advantag launch product
earlier competit pricing/reimburs coverag competitor might target
patient popul futur clinic trial although efficaci profil
page
phase ii studi superior current avail treatment market rehabilit
post-hip fractur competit
commerci risk vike previous launch market commerci product order
success commerci vike need establish salesforc well
secur payer coverag formulari decis base clinic data also
price well current avail agent current
unknown variabl indic nash fail cover
payer expect significantli diminish commerci prospect
financi risk vike like requir addit capit complet clinic develop
plan program invest thesi base vike abl secur suffici fund
competit yet untap nash space
introduct nash
non-alcohol steatohepat nash common often asymptomat diseas afflict
liver characterist manifest nash includ fat accumul inflamm result
damag liver liver respons detoxif metabol regul protein
synthesi anatom classifi one prime compon hepatobiliari system
nation institut diabet digest kidney diseas
nash belong larger famili liver diseas classifi collect non-alcohol fatti liver
diseas nafld medic condit character build-up fat liver adipos
tissu bodi fat deposit beneath skin and/or around intern organ primari depot
human bodi metabol store fat gener ectop accumul fat liver
organ uncommon indic pathogenesi two type fatti
infiltr liver nafld patient
non-alcohol fatti liver nafl benign condit fat infiltr mild
littl inflamm
page
non-alcohol steatohepat nash sever condit increas degre
fat deposit well inflamm steatohepat
short nafld nafl nash nash nafl term diseas sever seri key
definit understand nash space summar
exhibit non-alcohol fatti liver diseas relat definit
american associ studi liver diseas suntrust robinson humphrey
clinic liver biopsi need differenti nash nafl steatosi fat accumul
describ mild occur hepatocyt moder
hepatocyt sever hepatocyt patient nafl may foci lobular
inflamm mild portal inflamm defin featur steatohepat
hepatocellular injuri and/or fibrosi diagnosi nash requir find steatosi
hepatocyt injuri balloon degener indic liver cell death lobular inflamm
inflamm lobe liver fibrosi requir diagnost featur initi stage
fibrosi may present differ stage nafld address later report
caus pathogenesi nash fulli elucid wide accept theori
suggest insulin resist condit bodi respond adequ insulin
regul glucos homeostasi key effector lead nash
anoth pervas theori multi-hit hypothesi propos multipl environment
genet factor includ insulin impair inflamm dietari factor work togeth
result nash accord theori insulin resist alon suffici patient
develop nash character inflamm scar addit fat deposit
although possibl inflamm direct result fat accumul liver cell
damag biochem process known fat-induc peroxid gener free radic
grow evid suggest factor may also contributori factor includ
nuclear receptor involv insulin signal transduct leptin receptor modul
page
termnafldnaflnashnash cirrhosiscryptogen cirrhosisnafld activ score na definitionpres hepat steatosi inflamm hepatocyt injuri balloon without fibrosi progress cirrhosi liver failur rare liver cancer presenc cirrhosi current previou histolog evid steatosi steatohepatitispres cirrhosi obviou etiolog patient cryptogen cirrhosi heavili enrich metabol risk factor obes metabol syndrom unweight composit steatosi lobular inflamm balloon score na use tool measur chang liver histolog patient nafld clinic trial fibrosi score separ encompass entir spectrum fatti liver diseas individu without signific alcohol consumpt rang fatti liver steatohepat cirrhosispres hepat steatosi without evid hepatocellular injuri form balloon hepatocyt evid fibrosi risk progress cirrhosi liver failur consid minim vike inc
exhibit multi-hit hypothesi nash
suntrust robinson humphrey modifi sleiseng fordtran gastrointestin liver diseas
although on-going debat scientif commun regard exact caus
pathogenesi nash hinder research clinic effort find therapeut
treat nash approach drug develop quit similar seen therapeut
pioneer metabol diseas type diabet spite lack full
understand diseas etiolog type diabet mani class drug
success develop commerci target differ aspect diseas includ
ampk activ metformin ppar activ tzd drug class inhibitor
analog inhibitor etc address later report one interest aspect nash
therapeut space divers mechan pipeline-ag target highlight variou
approach pursu
decad mani risk factor identifi associ diseas includ
obes individu nash obes
diabet individu nash type diabet
hyperlipidemia individu nash hyperlipidemia
factor link nash includ insulin resist drugs/toxin amiodaron
cardiac dysrhythmia tamoxifen breast cancer steroid etc
nash affect signific number patient across spectrum
nash asymptomat difficult estim exact number nash patient given
time howev nash diagnos peopl undergon liver
biopsi age year although nash also occur children
young year age nash also preval women men
accord nation institut diabet digest kidney diseas nash affect
peopl addit popul nafl
epidemiolog studi report nafld preval biopsy-bas studi
confirm nash preval rest world nafld preval
report median
page
exhibit estim preval nafld nash world-wide
nafld common liver diseas industri world major risk
factor nafld includ obes type diabet dyslipidemia etc becom preval
nafld nash patient number correspondingli increas well past sever
decad obes map demonstr signific increas obes popul
 past two decad
note center diseas control cdc suntrust robinson humphrey
increas nafld time also exemplifi nutrit
examin survey conduct reveal increas trend
preval nafld account chronic
preval nafld account chronic
preval nafld account chronic
put size estim nash popul perspect compar nash well
character therapeutic-intens regard recent drug develop liver diseas
page
region popul studiedpreval nafld pediatr popul popul obes american american american pediatr popul popul countri gener popul diabet obes obes popul east gener popul east gener popul gener popul nafldpreval nash select healthi liver donor inamm brosi popul sever obes tertiari care center vike inc
hepat downward-revis cdc estim preval patient infect
hepat viru hcv approxim million individu compar six million
million individu nash hcv today multi-billion dollar market gilead hcv drug
sovaldi harvoni togeth gener billion peak sale make one
best-sel franchis time sovaldi current price per patient
cours therapi harvoni price per patient cours therapi
believ nash potenti dwarf hcv market due greater preval chronic
natur lack therapeut option commerci avail
nash progress diseas seriou clinic consequ
nash progress diseas patient asymptomat howev signific
risk progress seriou state seriou clinic complic cirrhosi
nation institut diabet digest kidney diseas
difficult predict clinic cours nash factor success identifi
diagnosi prognosi diseas without employ invas measur biopsi
studi bertot et al track liver damag nash patient year
demonstr condit improv peopl stabil peopl
worsen peopl studi period highlight irrevers natur
meta-analysi singh et al includ studi examin diseas progress
patient biopsy-confirm nafld nafl nash baselin
fibrosi stage rang mean fibrosi mean sever fibrosi
cirrhosi averag
approxim five year person-year follow-up patient progress
stabl fibrosi improv fibrosi stage nash sub-
patient improv fibrosi
meta-analysi conclud annual fibrosi progress rate patient
nafl stage fibrosi baselin stage ci stage compar
stage patient nash ci stage find correspond
stage progress year patient nafl ci
year patient nash ci
page
exhibit diseas progress nafl
nash progress cirrhosi occur liver becom sever scar one studi
found individu nash develop cirrhosi older women diabet
increas risk
nation institut
scar liver perform normal hepat function protein product cytokin
product blood-filt help digest food store energi cirrhosi lead
kidney failur jaundic sever itch gallston hepatocellular carcinoma
tissu scar gener non-revers current treatment aim control diseas progress
much scar tissu form cirrhosi lead need liver transplant even
transplant recurr nafld report
health-econom studi balistreri found nash patient liver-rel mortal
rate men women progress nash-rel cirrhosi
men women model establish public men women
develop nash-rel hepatocellular carcinoma men women
eventu requir liver transplant nash-rel cirrhosi lifetim medic cost
approxim nash patient led total nash-rel healthcar cost
nafld lead cirrhosi also associ cardiovascular diseas
cvd lead caus death report odd ratio nafld patient
develop cvd number signifi stronger correl higher
patient metabol syndrom
page
naflnashfirbosiscirrhosisliv failurehetatocellular carcinomanafl nashgener popul inflamm fibrosi sever obes fibrosispati tertiari referr center diagnosi high-risk sever obes cirrhosishigh-risk sever obes tertiari referr center diagnosi gener popul yearsgener popul yearsnash liver failurecirrhosi yearsnash hepatocellular carcinomacirrhosi per yearnafl cirrhosissimpl steatosi year vike inc
untap opportun nash treatment
current cure fda-approv therapeut treatment nash treatment
aim modifi risk factor control metabol condit commonli found nash patient
obes type diabet clinic manag nash gener consist
diabet control lifestyl chang low-calori low-fat diet increas physic
activ use fda approv drug obes type diabet well bariatr surgeri
extrem case sometim recommend note although weight loss potenti delay
progress nash believ individu effect gener difficult
maintain long term even follow bariatr surgeri signifi unmet medic need
therapeut treat underli caus nash
certain drug includ insulin sensit thiazolidinedion tzd anti-hyperlipidemia
agent prescrib certain case nash patient use drug nash off-
label indic efficaci drug treatment nash establish
well-control clinic studi
vitamin antioxid prescrib off-label treat nash clinic trial conduct
niddk compar vitamin metformin placebo pediatr nash patient
patient vitamin demonstr improv disappear nash contrast
patient metformin patient placebo achiev improv
howev studi fail meet primari endpoint sustain reduct alt serolog
test use measur liver injuri gener vitamin found benefici non-
diabet patient nash diabet nash nafld liver cirrhosi therefor
vitamin limit clinic util
suntrust robinson humphrey adapt dyson jk et al frontlin gastroenterolog
aasld guidelin publish suggest follow practic manag nafld
weight loss gener reduc hepat steatosi whether achiev either hypo-calor
diet alon conjunct increas physic activ
page
treatment intervent indic outcomediet calori restrict diet calori less daili requir aim lose satur fat simpl carbohydr sweeten drink aim lose bodi weight maintain loss loss bodi weight reduc steatosi balloon hepat inflammationexercis increas physic activ lower level steatosisreduc total sedentari time aerob exercis improv insulin min moder exercis improv liver enzym reduc liver fataerob resist high intens exercis effect aim steps/day pedomet orlistat enter lipas inhibitor achiev weight loss conjunct lifestyl modif alt steatosisonli continu loss bodi weight three month achievedbariatr surgeri primari treatment nash improv insulin sensit lipid profiletreat obes signific diseasereduc steatosi steatohepat fibrosisconsid first-lin option greater gastric bypass procedur effect produc sustain weight losspioglitazon recommend patient aggress nash fail lifestyl interventionsreduc hepatocellular injuri fibrosisconsid increas risk congest cardiac failur bladder cancer reduc bone densityvitamin reserv select patient advanc pre-cirrhot nash fail lifestyl interventionsimprov steatohepat vike inc
loss least bodi weight appear necessari improv steatosi
signific reduct weight may need improv necro-
exercis alon adult nafld may reduc hepat steatosi abil improv
aspect liver histolog remain unknown
metformin signific effect liver histolog recommend specif
treatment liver diseas adult nash metformin activ amp-activ protein
kinas ampk import enzym insulin signal result suppress glucos
product liver primarili prescrib anti-diabet recent metformin
increasingli use nafld clinic data complet true efficaci
yet determin
pioglitazon use treat steatohepat patient biopsy-proven nash
howev long-term safeti efficaci pioglitazon patient nash
establish
vitamin administ daili dose iu improv liver histolog non-diabet
adult biopsy-proven nash therefor consid first-lin
pharmacotherapi patient popul
vitamin recommend treat nash diabet patient nafld without liver
biopsi nash cirrhosi cryptogen cirrhosi
prematur consid foregut bariatr surgeri establish option specif
treat nash effect studi random control trial
statin use treat dyslipidemia patient nafld nash
random control studi conduct histolog endpoint support
efficaci statin use specif treat nash
test drug tzd believ evidence-bas data strongest
pathogenesis-bas rational treatment nash howev cardiovascular advers
effect weight gain safeti profil tzd long-term concern nash
receptor involv regul fatti acid storag glucos metabol howev
compound found associ seriou side effect troglitazon rezulin
order fda withdrawn market due liver toxic rosiglitazon
avandia caus increas risk heart attack although complet withdrawn
receiv strict restrict fda third drug pioglitazon acto associ
page
physician consult voic lack satisfact current therapi treat
result morbid associ nash underli issu address nash
nash sever form nafld howev within nash differ stage
broken clinic current investig nash agent target differ stage
diseas reflect inclusion/exclus criteria on-going studi conduct
trial result complet believ order accur map nash space
thorough understand diseas spectrum need
serolog test suggest measur diseas activ histolog evalu
provid accur diagnosi nafld liver biopsi still remain gold standard
reliabl method diagnosi prevail clinic trend establish nafld first
rel simpl criterion steatosi fatti liver assess grade sever accord
specif histolog observ howev due complex pathophysiolog nafld
lack defin diagnost criteria even among pathologist disagr
judg progress diseas
effort creat better standard assess degre pathogenesi nash
patholog committe nash clinic research network develop nafld activ
score na grade system address full spectrum lesion nafld assess
sever clinic trial natur histori studi nash clinic research network
sponsor nation institut diabet digest kidney diseas sinc one
major goal network design valid system histolog evalu
would cover spectrum nafld appli pediatr nafld allow assess
improv follow therapi
whole na system includ histolog compon within four evalu semi-
quantit score rest record present absent na score
calcul three four semi-quantit compon steatosi lobular inflamm
hepatocyt balloon compon assign score accord measur
specif symptom score steatosi measur percentag liver surfac area
involv steatosi evalu low-to-medium power examin score lobular
inflamm number foci per area examin score hepatocyt balloon
determin number cell balloon morpholog
page
note highlighted-in-r item includ calcul na highlighted-in-blu fibrosi stage suntrust
robinson humphrey modifi hepatolog
final total na score rang unweight sum biopsi individu
score steatosi lobular inflamm hepatocellular balloon
three categori featur activ injuri potenti revers short term
fibrosi measur scale fibrosi sever
form fibrosi cirrhosi fibrosi less revers gener thought result diseas
activ base fibrosi includ compon nafld activ score
howev view import measur nafld progress
origin studi design valid na system na score demonstr
strong correl diseas stage score seen case larg consid
page
itemdefinitionscore/codesteatosisgradelow- medium-pow evalu parenchym involv distribut patternzon steatosiscontigu patchesnot zone zone inflammationoveral assess inflammatori focino foci per foci per foci per aggreg lipogranulomasusu portal area adjac central inflammationassess low magnificationnon cell balloon cells/promin bodiesnon macrophagesnon findingsmallori hyalinevis routin stainsnon nucleicontigu patchesnon vike inc
diagnost nash score occur case larg consid diagnost nash
score evenli distribut non-diagnost borderlin diagnost case
nash therefor na score use determin stage diseas upon diagnosi
nash howev accord kol consult na limit util clinic practic
sever nafld gener broken-out nafl nash rather
granular score-bas system
liver fibrosi abnorm accumul extracellular matrix protein includ collagen
occur type chronic liver diseas advanc liver fibrosi lead cirrhosi liver failur
portal hypertens often requir liver transplant activ hepat stellat cell
portal fibroblast myofibroblast bone marrow origin major collagen-produc cell
injur liver activ fibrogen cytokin angiotensin ii leptin
differ stage fibrosi character morpholog acquir liver biopsi
accord studi kleiner et al detail na score system advanc
fibrosi stage correl higher percentag nash diagnos
exhibit patient nafld confirm nash na
suntrust robinson humphrey modifi hepatolog
within stage caus fibrosi differ fibrosi stage portal/periport
fibrosi larg due viral hepat hbv hcv differ fibrosi
observ nash mosti stage mild-to-moder perisinusoid fibrosi
centrilobular area adjancet central vein
diagnosi nash
gener clinic diagnosi nafld requir follow
demonstr hepat steatosi imag biopsi
exclus signific alcohol consumpt
exclus caus hepat steatosi
nafld asymptomat diseas patient gener diagnos consequ
routin test suspect nash patient elev liver enzym relev
diseas histori cascad addit test use confirm nash stage diseas
page
exhibit diagnost treatment algorithm nash
liver biopsi current refer standard nash diagnosi physician use histolog
confirm presenc nash assess extent hepatocellular balloon lobular
inflamm hepat fibrosi liver biopsi howev invas procedur small
signific risk complic bleed perfor death routin favor
patient provid moreov accumul fat liver tend distribut non-
uniformli lead inaccur assess diseas progress due spatial variabl
sampl techniqu also subject inter-observ variat limit make liver
biopsi sub-optimal tool clinic studi due inabl perform frequent liver biopsi
track diseas progress intrins imprecis unreli treatment end-point
impact trial size requir feasibl cost despit well-appreci limit
liver biopsi well avail variou non-invas imag techniqu biomark
unlik liver biopsi go away anytim soon accord kol nash panel
suntrust robinson humphrey clinic day confer june howev non-
invas imag techniqu biomark use conjunct liver biopsi clinic trial
correl assess use novel modal assess liver
biopsi establish physician consult believ new way diagnos nash
need multipl liver biopsi also becom impedi come patient enrol
page
nash trial result reliabl accur surrog end-point replac use
combin liver biopsi desir substanti import early-phas
clinic trial help ensur clinic trial find readili translat
measur routin practic
nation institut diabet digest kidney diseas
mri-pdff late studi extens gain popular field nash drug
develop mri-pdff quantifi hepat steatosi measur proton densiti fat fraction
fraction mri-vis proton bound fat divid proton liver bound fat
water diagnost accuraci consist valid sever studi
demonstr strong correl mri-pdff histolog liver biopsi techniqu
also demonstr higher degre precis reproduc reliabl compar histolog
assess less sensit intra- inter-observ variat importantli mri-pdff
highli respons chang hepat steatosi tradit liver biopsi histolog
assess fail detect advantag substanti especi preliminari short-term
studi resolut histolog reliabl patient like reluct
anoth liver biopsi month mani compani work nash incorpor
imag biopsi assess on-going plan studi recent madrig
nr report strong correl mri-pdff histolog liver biopsi
mri-pdff respond associ high probabl nash resolut
na score improv least two point although regulatori agenc approv
mri-pdff surrog biomark nash field evolv rapidli signific number
studi valid inher advantag techniqu
page
exhibit compani engag nash drug develop employ mri-pdff
fibroscan non-invas test use ultrasound determin stiff liver mean
elastographi use semi-quantifi level scar progress
cirrhosi ultrasound reveal hyperecho textur liver due diffus fatti infiltr
meta-analysi studi total patient found sensit specif
ultrasound respect howev sensit may decreas patient
morbidli obes fibroscan use consist patient chronic hcv diseas
techniqu detect sever fibrosi early-stag fibrosi therefor less practic
mr consid robust quantit mr-base method mri identifi
anatom locat liver steatosi mr compar chemic composit normal liver
tissu abnorm tissu sensit show strong agreement mri howev
limit technic demand avail therefor appli rel small
studi specialist center
discuss diagnosi section mani tool avail diagnos nash determin
sever diseas includ liver enzym mri/mr imag histolog
assess na score system also develop semi-quantit measur diseas
howev univers accept standard diagnosi diseas
made design clinic trial investig potenti nash therapeut challeng lack
standard make difficult compar result differ clinic trial
accord workshop organ american associ studi liver diseas
aasld primari ultim goal treat nash prevent liver-rel mortal
main caus liver-rel mortal cirrhosi aris gradual fibrosi
therefor recommend patient risk progress cirrhosi revers steatohepat
least worsen fibrosi use primari endpoint clinic trial primari
endpoint meet requir measur sensit chang clinic meaning
consist quantifi comorbid known close associ
page
nash bodi weight body-fat content insulin resist glycem indic well ast
alt level measur secondari endpoint
regard pediatr nash patient concern use liver histolog assess
primari endpoint may expos two liver biopsi howev ast alt
shown inadequ surrog endpoint altern non-invas marker
adequ valid pediatr patient tend variabl histolog spectrum
adult patient pediatr endpoint well defin adult endpoint therefor aasld
recommend use either revers steatohepat improv two point na
without worsen fibrosi endpoint biopsi need
clarifi regulatori guidelin regard nash clinic trial design septemb
fda aasld jointli sponsor workshop provid guidanc nash
therapeut develop joint workshop list clinically-meaning outcom nash patient
includ mortal patient function measur health statu patient
suntrust robinson humphrey modifi hepatolog
acknowledg workshop nash progress diseas progress
occur slowli order demonstr improv clinic meaning outcom
mortal larg number subject would need follow least year
would prohibit organ look develop drug nash workshop
establish guidelin surrog endpoint use nash clinic trial
page
hard clinic outcom mortalityall-causeliver-relatedliver-rel outcom drive mortal ascit complicationsvh varic hemorrhag hepat encephalopathi hepatocellular canceracute-on-chron liver failurehow patient functionsfunct statu disabl day work missed manag activ daili live patient feelssymptom physic healthment health vike inc
exhibit surrog endpoint early-stag diseas
note recommend sponsor plan use tool endpoint discuss plan fda accord fda
mechan pre-trial consult sh steatohepat suntrust robinson humphrey modifi hepatolog
particular interest use magnet reson imag tool measur reduct
steatosi non-invas imaging-bas techniqu potenti improv diagnost
accuraci reliabl respons although evid support correl
mri-pdff nash resolut believ tradit biopsy-bas endpoint still
need registr trial forese futur
anoth import outcom workshop separ advanc nash
fibrosi stage focu anti-fibrot therapi early-stag nash fibrosi
stage focu anti-nash therapi propos fda aasld
emphas heterogen nash popul
exhibit popul studi clinic trial nash
note sh steatohepat suntrust robinson humphrey modifi hepatolog
differenti thr- pathway pleiotrop benefit nash
thyroid hormon import regul growth develop metabol
action mediat triiodothyronin l-thyroxin tightli control
neg feedback system anterior pituitari releas thyroid stimul hormon tsh
blood level low high level inhibit releas tsh th level fall
page
endpoint commentdevelop cirrhosi clearli defin worsen health statu advers affect patient feel function surviv may serv primari endpoint full approv may measur biopsi modal diagnosi advanc fibrosis/cirrhosi liver stiff measur demonstr within time frame surrog prevent cirrhosi may suitabl subpart approv process requir long-term post-approv follow-up demonstr treatment prevent cirrhosi advanc fibrosis/cirrhosi may measur biopsi modal diagnosi advanc fibrosis/ cirrhosi liver stiff measur na need valid demonstr decreas reflect reduc risk advanc fibrosis/cirrhosi rel impact improv steatosi vs inflamm vs balloon clear mr quantif steatosi clinic accept valid tool requir fda accept tool valid use clinic trial use registr alt usual alway improv improv histolog decreas shown correl histolog improv trial subject stage diseas best suit earli phase proof concept phase i/iia studiesreduct hepat steatosi imag studi along decreas alt and/or marker cell injury/death sh without progress advanc fibrosi stage commentfor advanc stage diseas mainli antifibrot therapi biopsy-bas popul biopsy-bas populationsnash biopsi remain gold-standard despit sever limit bridg fibrosi cirrhosi non-biopsy-bas populationsnon-biopsi base popul steatosi mr spectroscopi diffusion-weight mr repres altern approach identif nash advanc fibrosi elev alt iu/l u/l advanc fibrosis/cirrhosi fda-approv non-invas method elastographi absenc altern caus liver diseasefor early-stag stage diseas anti-nash therapi nash biopsy-proven borderlin steatohepat grade greater inflammationpres balloon mallori bodi stage fibrosispersist elev alt previou month metabol syndrom popul probabl develop advanc fibrosis/ cirrhosi within year feasibl demonstr revers sh without fibrosi progress bridg cirrhosi within year recommend sponsor discuss fda pre-ind process entri criteria vike inc
enter cell transport protein although major form blood
convert activ hormon within cell bind nuclear thr function
ligand-depend transcript factor control express target gene
excess result therapeut desir effect increas metabol
rate lipolysi cholesterol lower improv heart contractil time
system thyrotoxicosi also result undesir effect includ tachycardia arrhythmia muscl
wast nervous fatigu loss bone mass
thr activ via bind thyroid hormon function transcript receptor
modul gene express hormon bind induc conform chang receptor
turn receptor transcript activ express varieti gene modul
lipid homeostasi metabol rate like member nuclear receptor superfamili
thr consist three function domain
transactiv domain n-terminu interact transcript factor
form complex repress activ transcript consider diverg
sequenc transactiv domain isoform two isoform
receptor
dna-bind domain bind sequenc promot dna known hormon
ligand-bind dimer domain c-terminu
date four differ thyroid hormon receptor isoform identifi
differ thr demonstr differenti express pattern vari
wide express especi high express cardiac skelet muscl
page
anterior pituitarythyroid glandconvers cell vike inc
homolog viral oncogen c-erb-a also wide express unabl bind
predomin express brain liver kidney
express primarili limit hypothalamu pituitari
thr- shown associ benefici effect increas free fatti
acid oxid mitochondria reduc progress steatosi subsequ inflamm
also promot cholesterol uptak activ apo receptor wherebi intern
particl metabol cholesterol compon becom part intracellular
cholesterol pool addit thr- found indirectli activ cholesterol uptak via bile
acid synthesi activ activ transcript cholesterol metabol enzym
perform first rate-limit step bile acid synthesi bile acid synthesi promot
convers cholesterol bile acid intestin excret mediat revers cholesterol
transport regul direct deplet intracellular cholesterol pool thr-
activ express hdl compon includ major protein
compon hdl requir re-absorpt hdl particl liver base
scientif public human anim studi nash liver defici thr- activ
lead featur nash includ steatosi inflamm fibrosi specif studi
shown thr- knock-out mice increas extent fibrosi delay apoptosi
consequ believ select thr- activ liver appeal target
therapeut intend address dysregul cholesterol triglycerid lipoprotein level
help combat root caus inflamm fibrosi found nash patient
previou failur thr- agonist clinic
base thr tissue-specif express pattern associ differenti function
effort made year develop -- specif agonist therapeut
metabol diseas goal achiev benefici effect thr- lower lipid
atherogen lipoprotein associ cardiovascular diseas induc weight loss
increas energi expenditur limit advers effect associ thr-
arrhythmia muscl wast bone loss suppress thyroid hormon axi tha
given key concern thr- agonist safeti profil ideal therapeut agent
therefor select thr- liver avoid advers effect thr- activ
exampl compound develop specif target thr- off-target effect
sobetirom eprotirom particular eprotirom develop karo pharma karo nr
modest -- select thyromimet display hepatic-select uptak data earli studi
investig eprotirom treatment hyperlipidemia human encourag show
robust lower cholesterol howev phase double-blind placebo-control trial
patient famili hypercholesterolemia eprotirom induc liver injuri indic
signific increas aspart aminotransferas ast alanin aminotransferas alt
level moreov parallel studi dog administr eprotirom month show
unfavor advers event cartilag result trial prematur termin six
studi conduct kelli et al assess function potenc select
reveal sobetirom eprotirom demonstr select thr-
page
thr- rel respect compound purport thr- select
receptor bind assay result contradict function coactiv recruit
assay relev indic select rel simpl receptor bind assay
provid inform compound abil act agonist
exhibit select thyromimet vitro function assay compar
adapt suntrust robinson humphrey research kelli martha et al
pleiotrop benefit ideal nafld nash treatment
oral avail liver-select agonist thr- belong famili novel
prodrug cleav vivo releas potent thyromimet live-target properti
deriv select activ cytochrom isozym
enzym found predominantli liver tissu gener elev hepat exposur activ
drug therefor reduc system exposur tissu heart
skelet muscl
equilibrium dissoci constant ki refer concentr drug
requir occupi avail receptor show high specif thr-
approxim select thr- thr- molecul also select liver
re-absorpt via hepat transport highli neg charg lead poor
passiv diffus thr- select proven radiograph tissu distribut
show low undetect uptak heart kidney brain result
believ shown superior select thr- high concentr liver coupl
liver-select activ reason low extrahepat permeabl contribut
safeti compound limit system exposur central thyroid axi suppress
page
compoundthr- thr- rel activ thr- rel activ vike inc
exhibit select thr- compar
select activ thr- liver tissu believ favor affect cholesterol
lipoprotein level via multipl mechan includ increas express low-dens
lipoprotein receptor increas hepat mitochondri fatti acid oxid
preclin studi demonstr cholesterol-low activ five anim speci
addit demonstr encourag cholesterol lower activ compar
atorvastatin approv wide prescrib medic lower cholesterol treatment
rodent also led benefici reduct liver fat content exampl histolog
evalu liver tissu well quantit data show liver triglycerid content reduc
rodent model hepat steatosi reduct liver fat content
suggest potenti benefit diseas character excess accumul lipid
liver tissu nash
exhibit demonstr potent cholesterol reduct rabbit monkey
june vike report posit top-lin data eight-week studi diet-
induc vivo model nash anim biopsi prior treatment ensur diseas
characterist consist human form diseas includ presenc fibrosi
treatment once-daili result statist signific reduct liver
page
triglycerid liver cholesterol total lipid non-alcohol fatti liver diseas activ score na
treat anim rel vehicl control specif anim demonstr
reduct total lipid content vs vehicl control
reduct liver triglycerid content vs vehicl control
reduct liver cholesterol content vs vehicl control
reduct na composit diseas activ compris steatosi balloon
exhibit significantli reduc steatosi diet-induc nash mous model
treatment also result statist signific reduct sever key measur
fibrot activ includ total liver fibrosi type collagen hydroxyprolin rel vehicl
reduct total liver fibrosi vs vehicl control
reduct type collagen vs vehicl control
reduct liver hydroxyprolin content vs vehicl control
exhibit improv fibrosi diet-induc nash mous model
page
moreov septemb vike announc posit result gene analysi conduct
part studi diet-induc vivo model nash treatment
result statist signific chang express key gene associ nash
develop progress rel vehicl control downregul gene import
de novo lipogenesi simultan stimul express gene import lipid
metabol summar anim demonstr
reduct express respect
increas express suggest improv lipid cholesterol
increas ppar express respect
suggest improv lipid metabol insulin sensit
reduct express
suggest reduc inflamm apoptosi oxid stress
reduct pro-fibrogen gene sma galectin
overal preclin studi demonstr promis result treatment
lower triglycerid cholesterol level improv lipid cholesterol metabol reduc
fibrot activ pleiotrop benefit suggest potenti address
underli metabol syndrom hallmark featur nafld nash well
hypercholesterolemia dyslipidemia
phase studi encourag efficaci safeti hypercholesterolemia nafld
exhibit clinic develop histori
evalu two phase trial first phase studi conduct
design evalu safeti toler pk profil second phase trial
initi complet phase ib trial random double-blind
placebo-control multipl ascend dose studi evalu safeti toler pk
patient mild hypercholesterolemia baselin plasma low-dens lipoprotein
consist liver- receptor-select mechan action demonstr dose-
depend reduct ldl-c triglycerid level day signific placebo-adjust ldl-c
placebo-adjust tg reduct baselin observ dose
rang approxim respect
page
exhibit lower triglycerid mild hypercholesterolemia patient
addit statist signific placebo-adjust reduct atherogen protein
lipoprotein lp apolipoprotein apo-b observ dose
previou studi demonstr lp apo posit associ patient
risk develop cardiovascular diseas
exhibit reduc lp apo-b patient mild hypercholesterolemia
term safeti shown safe well-toler dose level rang
rate advers event patient similar placebo-
treat patient seriou advers event report differ heart rate heart rhythm
blood pressur observ placebo-tr patient note howev
mild increas liver enzym observ higher dose along dose-
depend mean shift thyroid hormon level
page
on-going phase ii studi hypercholesterolemia nafld data expect
ii studi
current conduct phase
patient primari
hypercholesterolemia nafld trial random double-blind placebo-control
parallel group studi design evalu efficaci safeti toler
approxim patient elev ldl-c nafld patient random receiv
once-daili oral dose placebo week follow four-week off-drug phase
primari endpoint evalu effect treatment ldl-c week
compar placebo secondari exploratori endpoint includ assess chang liver
fat content use mri-pdff triglycerid inflammatori marker june vike
complet studi enrol compani expect report top-lin data
exhibit trial design phase ii studi hypercholesterolemia nafld
battl thr- agonist vs
madrig nr employ mechan action
select thr- agon therefor compar two drug select safeti
efficaci profil base result respect compound phase ib clinic trial
regard specif show approxim select thr- thr-
show approxim select thr- thr- note vike
madrig use method quantifi receptor specif thu direct
apples-to-appl comparison even thr- select higher
emphas prodrug cleav liver
enzym therebi releas potent thyromimet therefor reduc system exposur
tissu heart skelet muscl
exhibit select thr- thr- vs
suntrust robinson humphrey research compani report
differ quantif method determin receptor select
addit note demonstr consist pharmacokinet profil
compar plasma concentr activ time
proport dose-depend
page
compoundselect drug vike inc
exhibit plasma concentr day follow multipl dose
vike poster american colleg cardiolog confer suntrust robinson humphrey research
irregular pharmacokinet becom appar consid
dose employ phase ii trial specif cmax approxim
increas cmax doubl approxim
compar unfavor activ cmax proport
also note significantli higher cmax phase ii trial compar
cmax
exhibit cmax day multipl dose studi
suntrust robinson humphrey research compani report
dosag use phase ii studi
random placebo-control phase ib trial patient mild
hypercholesterolemia treat rang dose test safeti
efficaci demonstr statist signific placebo-adjust reduct
ldl-c dose reduct lp dose
page
day vike inc
 reduct apo-b well reduct triglycerid
dose compar result phase ib data demonstr
overal higher peak reduct measur
exhibit comparison result phase ib studi
suntrust robinson humphrey research compani report
addit compound shown safe well-toler studi dose
report treatment- dose-rel seriou advers event howev mention earlier mild
asymptomat elev liver enzym decreas thyroid hormon level observ
higher dose one case grade alt ast elev time upper
limit normal uln also report howev liver enzym elev transient revers
normal without dose interrupt compar unfavor
demonstr statist signific lower liver enzym well reduct total
phase ib trial well phase ii studi although elev liver enzym decreas
thyroid level asymptomat increas alt level may indic potenti liver injuri
believ safeti data larger trial valid concern regard liver enzym elev
patient believ conveni safeti profil crucial nash patient
look studi design phase ii studi emphas target
broader patient popul nafld/hypercholesterolemia precursor nash develop
focus nash patient trial includ patient biopsy-
proven nash na fibrosi liver fat content pdff-mri compar
inclus criteria liver fat content pdff-mri ldl-c
triglycerid regard trial endpoint vike primari endpoint chang ldl-
 patient receiv compar placebo madrig primari endpoint chang
baselin hepat fat fraction assess mri-pdff madrig also includ biopsi data
na score nash resolut fibrosi score secondari endpoint result
indic nash prefer madrig trial design target cohort phase ii
trial provid relev data compar broader focu also given liver
biopsi definit method diagnos nash vike abl conduct post hoc
page
doseldl-c chang tg chang lp chang apob mg mg mg mg mg mg mg phase ib doseldl-c chang tg chang lp nmol/l baselineapob mg mg mg mg mg mg phase ib vike inc
analysi nash subpopul phase ii studi addit phase ii studi nash
need vike plan pursu nash indic
data provid valuabl read-through phase ii
may madrig announc posit result phase ii studi nash
week data demonstr sustain highli statist signific reduct liver fat
compar placebo mri-pdff patient treat mean
rel fat reduct compar placebo group mean reduct
patient receiv also achiev sustain statist signific reduct
nafld/hypercholesterolemia patient believ promis lipid-low result mgl-
provid valuabl read-through phase ii data expect believ
upcom phase ii data readout significantli de-risk employ
mechan action data compani phase ib trial correspond fact
show superior efficaci lipid atherogenic-ag lower
triglycerid apob lp although phase
view mri-pdff result phase ii studi crucial allow
direct comparison phase ii data nash compound candid
note vike enrol patient popul nafld hypercholesterolemia milder diseas
look forward see factor affect final data readout anoth critic
compon glean upcom top-lin phase ii result potenti off-target
effect evalu total safeti data bilirubin alt
ast safeti signal mild believ result could creat signific valu
appreci share
futur clinic pathway nash
result phase ii studi posit vike express strong interest pursu
nash specif ideal compani conduct nash-ded phase ii/iii studi
biopsi perform phase ii portion six nine month treatment
patient enrol larger longer phase extens studi reduc time gap
phase ii phase portion circumv slow enrol experienc
current phase ii studi vike conduct glp toxic studi establish safeti margin
dosag potenti allevi strict enrol criteria use on-going phase ii
specif exclus patient atherosclerot cardiovascular risk result
toxic studi expect end earli compani plan meet
fda discuss phase ii/iii studi design data glp toxicolog studi
on-going phase ii studi nafld hypercholesterolemia posit base posit read-
out vike plan file ind gastrointestin divis fda
nash space seen grow number player enter field past year
investig nash agent employ differ mechan action target differ subset
nash patient popul
page
exhibit summari nash agent clinic develop
interest aspect nash clinic develop space divers mechan
pipelin agent employ highlight divers diseas variou approach
pursu overal nash spectrum agent develop broken candid
primarili target nash oca candid primarili target fibrosi
simtuzumab candid potenti address concern
oca primarili target metabol nuclear receptor may broad activ
regul variou metabol pathway emricasan cenicriviroc focu inflamm anti-
fibrot agent target extracellular matrix network
view thr- agon promis approach treat nash unlik pathway
rais ldl-c fxr triglycerid antagonist thr- agon reduc
plasma triglycerid ldl-c may provid cardiovascular benefit nash patient thr-
agonist reduc liver fat breakdown fatti acid stimul mitochondri
biogenesi liver therebi reduc lipotox improv liver function although thr-
agon valid directli caus fibrosi reduct liver fat shown
benefit histolog assess liver biopsi also increas recognit
liver fibrosi decreas time nash resolv similar reduct fibrosi liver
regener erad hcv
recent deal nash space
recent deal nash space indic high level interest indic big
pharma biotech compani alik case allergan gilead deal reflect
wide held belief physician compani treatment regimen nash
requir therapeut combin approach rather monotherapi
page
candidatemechanismcompanyphasenobetichol acidfxr signal regul kinas signal regul kinas chemokin co-receptor chemokin co-receptor caspas caspas caspas ppar polysaccharid agonist ppar signal regul kinas carboxylas hormon receptor select variant hormonengm vike inc
exhibit select deal nash
compani report press releas suntrust robinson humphrey research
undisputedli nash gain lot attent pharmaceut biotechnolog compani
due sizeabl revenu potenti unmet need indic offer first-mov
advantag certainli signific believ room multipl player broad
space similar ubiquit market statin anti-diabet
overal acknowledg caveat associ small clinic trial
nonetheless encourag dose-depend reduct atherogen lipid marker
lp apob also observ downregul pro-fibrogen gene
includ sma galectin preclin studi believ could becom
attract nash drug given address thr- agonist histor selectivity/safeti issu
pleiotrop effect characterist ideal nash drug address cardiovascular risk
lead caus death within nash popul differenti competitor
diseas background hip fractur
hip fractur break occur upper part femur thigh bone accord center
diseas control prevent hip fractur caus fall
specif fall sideway delay recognit hip fractur result increas
morbid mortal mortal rate within one year hip fractur rang
one recent studi found risk die fractur one year could reach high
approxim half patient lose abil live independ follow hip fractur
major face on-going disabl prolong institution
typic symptom hip fractur sever pain around hip particularli movement
usual inabl walk physic examin commonli reveal abduct extern
rotat hip shorten affect leg patient usual local tender
hip limit rang motion affect leg attempt rotat flexion
page
upfronttotalnovartisconatusworldwid rightsemricasanphas evogliptinphas cencriviroc phase invest programphas typedrugstatu vike inc
patient experi hip fractur year age
 popul annual incid hip fractur expect increas
gullberg et al et al found hip fractur among
expens condit seen hospit aggreg cost nearli
approxim annual total individu hospit hip
fractur accord data agenc healthcar research qualiti
ahrq patient hip fractur older elderli individu
higher risk substanti morbid mortal result higher rate frailti
undernourish furthermor year age rate hip fractur increas
age doubl everi five six year women often affect men hip fractur
primarili due fact women often suffer osteoporosi diseas weaken
bone make like break
exhibit annual incid hip fractur
diagnosi hip fractur usual establish detail histori thorough
physic examin plain-film radiograph symptomat hip x-ray affect hip
usual make diagnosi obviou take radiograph front anteroposterior view
side later view full-length thigh bone knee film also frequent obtain initi x-
ray neg fractur still suspect magnet reson imag mri comput
tomographi ct bone scan employ confirm diagnosi variou studi
demonstr mri modal accur cost-effect ct bone scan
mri second test choic radiograph find indetermin
page
patient hospit hip fractur y/o vike inc
exhibit x-ray typic hip fractur
hip fractur usual classifi accord anatom locat hip fractur typic
classifi intracapsular extracapsular intracapsular fractur includ femor head femor
less commonli greater lesser trochanter fractur fractur
categor fractur pattern fractur stabil garden classif system
use categor intracapsular hip fractur femor neck
differ intracapsular extracapsular fractur make prognosi distinct earli
detect intracapsular fractur especi import fractur prone
complic intracapsular fractur could disrupt blood suppli femor head lead
avascular necrosi addit head fragment fractur often shell contain fragil
cancel bone provid poor anchorag fixat devic situat often increas
possibl non-union failur fractur heal mal-union heal fractur
patient hip fractur requir surgic reduct intern fixat surgic treatment
outweigh risk non-surg treatment requir extens bedrest howev choic
surgic procedur depend type fractur prefer orthoped surgeon
page
sever injuri age patient presenc absenc comorbid condit
osteoporosi prognosi recoveri rehabilit
hip fractur chang bodi composit
total bodi mass consist three compon fat mass lean mass bone fat mass lean
mass demonstr opposit unfavor pattern chang hip fractur studi show
follow hip fractur patient experi sever rapid declin lean bodi mass lbm
bone miner densiti bmd fat mass increas lean mass decreas
older femal hip fractur patient year hip fractur older women
gain fat mass lose lean mass per year signific loss lbm
appear occur two four month fractur loss muscl mass well muscl
strength demonstr associ impair physic function studi
conduct di monaco et al also demonstr higher low appendicular lean mass alm
predict significantli improv short-term function recoveri male patient hip fractur
hip fractur averag loss bmd baselin rang month
differ affect region thigh bone lower bone miner densiti follow hip fractur also
demonstr associ increas disabl recurr fractur mortal thu
prevent deleteri chang bodi composit could profound clinic implic hip
androgen receptor select androgen receptor modul sarm
androgen import proper regul reproduct system play critic role
homeostasi muscular skelet cardiovascular metabol central nervou
system androgen exert action via androgen receptor ar steroid-hormon nuclear
transcript factor dna binding-depend manner regul target gene transcript
non-dna binding-depend manner initi rapid cellular event phosphoryl
ar compris three main function domain n-termin transcript regul domain
dna bind domain ligand bind domain lbd n-termin domain
ar variabl whilst highli conserv region differ
member steroid hormon nuclear receptor famili dbd steroid hormon nuclear
receptor consist two zinc finger recogn specif dna consensu sequenc zinc
finger facilit direct dna bind ar promot enhanc region ar-regul
gene therebi allow activ function n-termin lbd stimul repress
transcript gene link lbd hing region transcript
activ function identifi ligand-independ locat n-termin
domain ligand-depend locat ligand bind domain nuclear local
signal nl respons import receptor nucleu nuclear export signal
ne respons export ar cytoplasm upon ligand withdraw locat
hing region lbd respect
page
androgen select androgen receptor modul sarm
testosteron major ligand androgen receptor testosteron predomin produc
test men adren gland ovari women lower level men
testosteron exert anabol effect stimul growth muscl bone well
androgen effect stimul growth prostat sebac gland sinc
testosteron divers rang physiolog function human consid non-tissue-
select androgen potenti achiev muscl bone remodel gain skelet
muscl mass strength testosteron supplement substanti howev administr
supra-physiolog dose androgen associ high frequenc dose-limit advers
effect erythrocytosi leg edema prostat event furthermor testosteron must
administ intramuscular inject transderm patch gel rout administr
inconveni associ potenti safeti issu
select androgen receptor modul sarm class androgen receptor ligand
bind androgen receptor display tissue-select activ androgen signal sarm
design elicit anabol benefit androgen testosteron muscl bone
without advers affect prostat cardiovascular outcom therefor therapeut agent
sarm would attract function promot anabol therapi function
limit disabl associ chronic disord age frailti cancer cachexia
differenti interact sarm ar contribut uniqu pharmacolog action
ligand bind induc specif conform chang ligand bind domain
modul surfac topolog protein-protein interact ar co-regul result
tissue-specif gene regul preclin studi demonstr abil sarm
increas muscl bone mass preclin rodent model vari degre prostat spare
oral avail non-steroid sarm belong famili novel non-
steroid sarm compound base tissue-specif gene express function featur
third-gener sarm greatli improv tissue-select compar earlier-
demonstr anabol activ muscl anti-resorpt anabol activ bone
robust select muscl bone versu prostat sebac gland anim model
femal rat model shown benefici effect muscl mass multipl site
page
exhibit increas skelet muscl mass femal rat
preclin model osteoporosi demonstr improv bone miner densiti
bone miner content bone strength measur
exhibit benefici effect cortic bone osteoporosi rat model
furthermor daili dose induc signific progress weight gain
primat gain retain four-week recoveri period
exhibit promot weight gain non-human primat
page
clinic develop histori
exhibit clinic develop histori
evalu phase clinic trial studi random double-blind
placebo-control trial healthi male volunt conduct clinic trial six cohort
receiv singl ascend dose sad rang primari
endpoint evalu safeti toler escal singl dose healthi
male subject secondari endpoint trial determin pharmacokinet pk
pharmacodynam pd sad healthi male subject result show
singl dose level administ well-toler seriou sever advers event
observ among subject receiv pd result show dose-depend
decreas total testosteron sex-hormon bind protein consist mechan
action select androgen receptor modul dose-depend decreas fast serum high-
densiti lipoprotein hdl also observ well-toler demonstr
predict dose-proport increas system exposur
second phase multipl ascend dose mad studi initi total
healthi men three cohort dose daili placebo
day primari endpoint trial assess safeti toler escal dose
follow repeat once-daili oral administr day healthi men secondari
endpoint determin pk pd follow repeat once-daili oral
administr day exploratori endpoint includ determin effect day
treatment lbm measur dual energi x-ray absorptiometri scan maxim
voluntari strength measur one repetit maximum method physic function
assess stair climb power averag bodi mass index cohort rang
trial subject receiv dose demonstr
statist signific averag increas lbm posit dose-depend trend strength
perform measur also observ signific chang trend
page
dose escal dose escal dose escal studi elderli studycomplet inc
exhibit increas lbm muscl strength men
shown safe well toler similar frequenc advers event
treat placebo group drug-rel seriou advers event
studi discontinu due advers event addit clinic signific chang
hemoglobin prostate-specif antigen liver enzym electrocardiogram dose
also display favor pk profil display prolong elimin half-lif hour
linear pk plasma concentr approxim three-fold higher day
day indic accumul upon multipl dose
phase multipl escal studi elderli subject
octob vike complet phase clinic trial healthi male femal
subject age studi conduct evalu safeti toler
pharmacokinet elderli subject subject receiv once-daili oral dose
seven day result show safe well toler dose evalu
seriou advers event observ subject receiv schedul dose addit
demonstr pharmacokinet properti similar previous report younger
phase ii proof-of-concept studi hip fractur
phase ii proof-of-concept trial random double-blind placebo-control intern
studi design evalu efficaci safeti toler patient recov
hip fractur surgeri total patient random receiv once-daili dose
placebo week
page
exhibit design phase ii trial
novemb vike announc posit top-lin result trial achiev primari
endpoint demonstr statist signific dose depend increas lbm follow
treatment compar placebo studi also achiev certain secondari
endpoint demonstr statist signific increas appendicular lbm total lbm
dose compar placebo specif
dose demonstr statist signific increas total lbm studi
primari endpoint placebo-adjust increas lbm
 correspond placebo-
adjust increas
proport patient experienc least increas total lbm
placebo
proport patient demonstr least gain total lbm less head
placebo
dose produc statist signific increas appendicular lbm
secondari efficaci endpoint placebo-adjust increas appendicular lbm
correspond placebo-adjust increas
dose produc statist signific increas total lbm includ
secondari efficaci endpoint placebo-adjust increas lbm
 correspond
placebo-adjust increas
page
also demonstr encourag safeti toler signific differ
rate advers event report among patient receiv compar placebo
dose-rel differ report advers event among treatment
group addit drug-rel seriou advers event observ patient receiv
exhibit well-toler
compar therapeut compound use differ mechan action
testosteron analog myostatin-target approach clinical-stag sarm
demonstr significantli higher potenc lean bodi mass increas led least
improv lean bodi mass compar favor development mechan
page
exhibit lbm improv older adult compound treatment
vike plan present data american societi bone miner research
asbmr confer late septemb demonstr long-term safeti durabl
treatment note patient treatment follow-up period addit
vike current explor option advanc compani seek fda feedback
regard data gener date potenti registr path forward partner discuss
licens opportun also underway
potenti stress urinari incontin pend data gtx ebonosarm
manag express interest pursu indic stress urinari
incontin also sizeabl access market high unmet need
effect treatment condit wherebi unintent leakag urin occur
normal daili activ increas abdomin pressur cough sneez run
lift heavi object inabl control urin flow occur involv sphincter
support muscl becom weak function properli muscl lose tone age
urolog foundat approxim one three women suffer especi
increas age half women year age develop current
approv therapi
gtxi nr develop enobosarm current run placebo-control phase ii trial
postmenopaus women primari endpoint percentag patient least
reduct number stress incontin episodes/day assess three-day void
diari result enobasarm posit vike plan assess potenti therapeut role
given appear higher peak efficaci levitor ani la
muscl significantli lower dose head-to-head preclin studi compar
enobosarm potenc note increas la muscl strength put mechan behind
improv outcom stress urinari incontin plan report data on-going phase
ii studi octob view repres attract opportun compar
orthoped rehabilit hip fractur market given limit competit size
address patient popul effect treatment could potenti becom
blockbust asset opinion
page
exhibit potenc compar favor enobosarm
castrat male rat treat restor mode day castrat control intact control
glycogen storag diseas type ia gsd ia rare autosom recess genet disord
character accumul glycogen fat liver kidney gsd ia caus
defici lead inabl metabol glycogen
glucos thu lead excess glycogen accumul bodi tissu low level glucos
blood imbal glycogen glucos level lead imbal lipid
triglycerid diseas result accumul glycogen lipid liver
potenti lead hepat steatosi liver failur develop hepat adenoma
hepatocellular carcinoma symptom usual begin three four month age fatal
gsd ia incid approxim one live birth incid rate suggest
new case per year new case per year eu current
estim preval approxim patient
gsd ia treat special diet maintain normal glucos level prevent hypoglycemia
maxim growth develop frequent small serv carbohydr throughout day
must maintain throughout life uncook cornstarch use improv glucos level
calcium vitamin iron supplement often recommend allopurinol may use
reduc level uric acid blood control gout-lik arthriti adolesc year
addit medic may employ lower lipid level prevent kidney diseas kidney
liver transplant consid therapi unsuccess
page
compar enobosarm higher peak efficaci levitor ani la muscl significantli lower dose head-to-head preclin studi potenc vike inc
exhibit gsd ia pathophysiolog potenti modul lipid
data support clinic investig gsd ia data expect
due extens diseas burden seriou morbid potenti therapi could revers
slow diseas progress could signific posit impact patient qualiti life
gsd ia patient receiv continu dietari intak slow-releas cornstarch order
reduc hypoglycem episod control diet reliev symptom address
underli caus gsd ia
vike investig potenti treatment gsd ia given abil lower
triglycerid reduc steatosi improv lipid profil preclin clinic studi
compani conduct proof-of-concept trial vivo mous model gsd ia
gene encod knock knockout mous model
replic biochem physiolog characterist present gsd ia patient
hypertriglyceridemia steatosi
four day once-daili treatment mice demonstr
reduct mean liver triglycerid compar placebo
similarli mean liver weight decreas though
statist signific mice receiv treatment show mean liver triglycerid
concentr reduct note triglycerid
concentr take account volum liver usual shrink treatment
triglycerid content factor potenti explain discrep regard statist
signific two data set
page
exhibit significantli reduc liver fat gsd ia mous model
base encourag preclin data vike plan initi proof-of-concept phase studi
assess safeti pharmacokinet efficaci gsd ia patient come
week studi enrol approxim ten patient trial primari endpoint
triglycerid content hepatocyt assess though dose disclos
trial allow dose adjust vike manag mention gsd ia patient
alreadi identifi compani plan report result studi final
note success address hypertriglyceridemia steatosi symptom gsd
ia prevent hepat adenoma hepatocellular carcinoma patient still need anoth
treatment hypoglycemia slow-releas cornstarch
x-link adrenoleukodystrophi x-ald rare genet neurodegen disord caus
mutat peroxisom transport long chain fatti acid vlcfa known atp-
bind cassett transport result poor absent protein function
vlcfa metabol properli instead accumul variou tissu
devast manifest vlcfa accumul impact central nervou system
wherebi abnorm persist inflamm occur inflammatori respons often result
demyelin loss sheath surround nerv cell nourish help conduct
electr impuls turn loss brain function x-ald broad spectrum clinic
manifest sever childhood cerebr ald cald character progress
inflammatori demyelin brain mild form adrenomyeloneuropathi
diseas link chromosom x-ald primarili affect boy initi children may
misdiagnos attent deficit hyperact disord learn disabl may
initi respond pharmacolog stimul howev brain function may begin deterior
accompani behavior abnorm blind loss movement accord
nation librari medicin preval x-ald individu world-wide
page
current cure diseas hematopoiet stem cell transplant repres
potenti treatment option patient match donor howev small minor
patient sibl human leukocyt antigen hla -match donor major
transplant use partial match non-ident sibl mismatch donor
transplant procedur lead signific risk graft vs host diseas fatal
exhibit mutat gene lead x-link adrenoleukodystrophi
show earli promis mous model x-ald expect ind
anoth thr- agonist vike prodrug cleav liver
carboxylesteras releas activ drug moieti compound structur differ
select thr- thr-
base multipl studi includ fourcad et al hartley et al thr- agon
increas gene express gene encod homolog peroxisom transport
abil rescu defect phenotyp well restor vlcfa metabol
vike plan leverag upregul increas express altern
mous model mimic biochem featur human x-ald once-
daili dose led robust reduct plasma level lysophosphatidylcholin
lpc deriv vlcfa ester specif plasma
level reduc
respect note key diagnost biomark x-ald reduc
level shorter chain vlcfa suggest enhanc reduct time via
deplet pool chain elong importantli reduct plasma vlcfa
gener maintain increas magnitud statist signific cours
studi suggest potenti progress durabl effect
page
exhibit led reduct plasma vlcfa-lpc mous model
treatment also led signific reduct vlcfa
level brain spinal cord liver tissu particularli impress strong
effect vlcfa reduct brain spinal cord vike conduct addit
preclin experi understand potenti mechan behind observ benefit
includ radiolog analysi local drug distribut import
organ examin whether activ drug cross blood-brain barrier
exhibit reduc vlcfa level tissu
although earli develop believ preclin result demonstr signific
reduct vlcfa level plasma vital organ attract goal therapeut
approach x-ald vlcfa accumul believ contribut underli patholog
diseas vike plan file ind potenti start phase proof-of-concept studi
page
therapeut asset base small molecul
vike
ligand
nr pursuant master licens agreement may ligand
grant vike exclus perpetu irrevoc world-wide royalty-bear right licens
patent relat fructos inhibitor
erythropoietin receptor agonist epor program diacylglycerol o-acyltransferas inhibitor
program exchang vike issu share common stock ligand
exhibit regulatori mileston sale mileston sale royalti ligand
march ligand held approxim vike outstand common stock
brian lian ph presid chief execut offic
dr lian serv presid chief execut offic prior join vike manag
director senior research analyst suntrust robinson humphrey cover small-
mid-cap biotechnolog compani emphasi diabet oncolog infecti
diseas neurolog space also execut director senior biotechnolog
analyst cibc world market prior career equiti research research scientist
microcid pharmaceut dr lian hold account financ
indiana univers ph organ chemistri univers michigan
ba chemistri whitman colleg
michael morneau vice presid financ administr
mr morneau serv vice presid financ administr prior vike vice-president
financ chief account offic triu director lilli
research lab financ eli lilli compani director financ account sgx
pharmaceut prior sgx control momenta pharmaceut mr morneau
earn master art account new hampshir colleg ba
mathemat univers new hampshir
page
compounddevelop regulatori milestonessal per indic two indic singl per indic three indic singl per indic four upon first commerci sale singl digitepor per indic three indic singl per indic two indic singl digit vike inc
ms mancini serv senior vice presid clinic oper ms mancini
year experi pharmaceut biotechnolog industri focus manag
oversight clinic trial early-stag late-stag drug develop prior join
vike senior director clinic oper ambit bioscienc corpor senior
director clinic oper serv
senior director project manag clinic oper ms mancini global director
clinic oper overse baxter bioscienc global clinic trial ms mancini hold
bioethic loyola marymount univers univers phoenix bs
nutrit scienc mcgill univers
dr masamun ph serv senior vice presid pharmaceut develop prior
join vike vice presid product develop palkion
inc prior palkion dr masamun serv senior director pharmaceut scienc
neurogen corp previous spent year drug discoveri develop work
area cardiovascular pulmonari infecti diseas earn bs organ
chemistri univers wisconsin ph organ chemistri univers
page
overal believ vike compens structur align sharehold interest in-
line compani focus nash diseas relat bone well
commensur biotech industri standard
page
vike market cap positionyearsalary/fe bonus/oth stock award option award total market cap positionyearsalari bonus/oth stock award option award total market cap positionyearsalary/fe bonus/oth stock award option award total market cap positionyearsalary/fe bonus/oth stock award option award total cnat market cap positionyearsalary/fe bonus/oth stock award option award total health market cap positionyearsalary/fe bonus/oth stock award option award total comparison purpos comp list chose highest paid senior manag board develop officergener counselgreg ph brent hatzis-schochjesp hoilandevp cfoevp clinic developmentpresid ceosteven mento ph david hagerti keith marshal ph presid ceoceocmosvp csosuj shahpol boud charl mcwhertersandip kapadiadavid shapiro ceocfocmoaverag total comp ceoaverag total comp positionsmichael morneaubrian lian ph lawson macartney ph chairmanceovp financ adminceocmo evp dsvp cfopaul friedman rebecca taub marc schneebaummark pruzanski vike inc
compani file suntrust robinson humphrey research
page
vike incom statement revenuestot sale revenu nash us mm -- -- -- -- -- -- -total royalti revenu mileston nash book vike mm -- -- -- -- -- -- -total royalti revenu mileston hip fractur book vike mm -- -- -- -- -total revenu -- -- -- -- -- -- -oper expens cog -- -- -- -- -- -- research gener oper loss expenseschang fair valu accru licens fee -- -- -- -- -chang fair valu debt convers featur debt financ incom loss rate -- -- -- -- -- -- -incom tax -- -- -- -- -- -- -net incom incom loss per share share outstand vike inc
compani file suntrust robinson humphrey research
page
revenuestot sale revenu nash us royalti revenu mileston nash book vike royalti revenu mileston hip fractur book vike expens research gener oper loss expenseschang fair valu accru licens fee -- -- -- -- -chang fair valu debt convers featur debt financ incom loss incom incom loss per share share outstand vike inc
vike clinical-stag biopharmaceut compani focus develop
novel therapi metabol endocrin disord compani clinic program includ
phase ii develop nafld hypercholesterolemia phase ii trial
hip fractur recoveri phase ib proof-of-concept studi gsd ia x-ald
ind expect phase ii/iii trial nash also expect initi
base final top-lin data on-going phase ii nafld hypercholesterolemia
vike develop select thr- agonist treatment nash result
preclin trial phase ib studi encourag demonstr pleiotrop benefit
lower triglycerid ldl-c well atherogen lipid lp apo-b
address underli metabol syndrom hallmark featur nash includ steatosi
lipotox inflamm balloon potenti cardiovascular benefit also make
valu agent potenti treatment nash address lead caus death within
nash popul differenti competitor space de-risk readout
phase ii studi hypercholesterolemia nafld expect vike also develop
hip fractur recoveri result phase ii studi present novemb
demonstr statist signific dose-depend increas lean bodi mass follow
week treatment compar placebo also demonstr significantli higher potenc
lean bodi mass increas compar therapeut compound use differ mechan
action testosteron analog myostatin-target approach clinical-stag
sarm phase ib studi gsd ia ind expect file
x-ald indic repres addit upsid price target
valuat risk
price target determin take averag three differ methodolog
discount earn model discount cash flow model clinic net present valu model
discount earn model appli multipl discount back discount
cash flow model employ industri standard discount rate perpetu growth
rate conserv clinic npv model estim peak revenu book vike
approxim nash hip fractur recoveri out-year
model assign success probabl nash hip fractur recoveri base
clinic profil demonstr date
risk rate price
clinic risk efficaci safeti profil encourag phase ib studi
nafld hypercholesterolemia impress met primari endpoint phase ii
trial hip fractur recoveri guarante futur clinic success
regulatori risk despit promis data clinic trial date promis data
report futur pivot trial guarante fda approv
competit risk sever compani develop therapeut treatment nash
believ differenti due pleiotrop benefit nash benign safeti profil
howev compet therapeut may first-to-market advantag launch product earlier
competit pricing/reimburs coverag competitor might target patient
popul futur clinic trial although efficaci profil phase ii
studi superior current avail treatment market rehabilit post-hip fractur
competit
commerci risk vike previous launch market commerci product order
success commerci vike need establish salesforc well
secur payer coverag formulari decis base clinic data also
price well current avail agent current
unknown variabl indic nash fail cover payer
expect significantli diminish commerci prospect
financi risk vike like requir addit capit complet clinic develop
plan program invest thesi base vike abl secur suffici fund
page
compani mention note
edward nash herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
